Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

por Miguel, Antonio, Sendra, Luis, Noé, Verónica, Ciudad, Carles J, Dasí, Francisco, Hervas, David, Herrero, María José, Aliño, Salvador F
Publicado 2017

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

por Cassinello, J., Arranz, J. Á., Piulats, J. M., Sánchez, A., Pérez-Valderrama, B., Mellado, B., Climent, M. Á., Olmos, D., Carles, J., Lázaro, M.
Publicado 2017

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

por del Muro, X García, Marcuello, E, Gumá, J, Paz-Ares, L, Climent, M A, Carles, J, Parra, M Sánchez, Tisaire, J L, Maroto, P, Germá, J R
Publicado 2002

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

por Carles, J, Font, A, Mellado, B, Domenech, M, Gallardo, E, González-Larriba, J L, Catalan, G, Alfaro, J, Gonzalez del Alba, A, Nogué, M, Lianes, P, Tello, J M
Publicado 2007

1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospita...

por García-Illescas, D., Saoudi Gonzalez, N., Mirallas, O., Aguilar-Company, J., Ruiz-Camps, I., Garcia-Alvarez, A., Lostes Bardaji, M.J., Valdivia, A., Marmolejo Castaneda, D.H., Rezqallah Aron, M.A., López Valbuena, D.E., Felip, E., Carles, J., Tabernero, J.
Publicado 2020

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus ab...

por de Wit, R., Wülfing, C., Castellano, D., Kramer, G., Eymard, J.-C., Sternberg, C.N., Fizazi, K., Tombal, B., Bamias, A., Carles, J., Iacovelli, R., Melichar, B., Sverrisdóttir, Á., Theodore, C., Feyerabend, S., Helissey, C., Foster, M.C., Ozatilgan, A., Geffriaud-Ricouard, C., de Bono, J.
Publicado 2021

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAM...

por Alcaraz, A, González-López, R, Morote, J, de la Piedra, C, Meseguer, C, Esteban, E, Climent, M, González-Gragera, B, Álvarez-Ossorio, J-L, Chirivella, I, Mellado, B, Lara, P-C, Vázquez, F, Contreras, J-A, Carles, J, Murias, A, Calderero, V, Comet-Batlle, J, González-del Alba, A, León-Mateos, L, Mañas, A, Segarra, J, Lassa, A, González-Enguita, C, Méndez, M-J, Samper, P, Unda, M, Mahillo-Fernández, I, Bellmunt, J
Publicado 2013

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastase...

por de la Piedra, C, Alcaraz, A, Bellmunt, J, Meseguer, C, Gómez-Caamano, A, Ribal, M J, Vázquez, F, Anido, U, Samper, P, Esteban, E, Álvarez-Ossorio, J L, Lara, P C, San José, L A, Contreras, J A, del Alba, A G, González-Gragera, B, Tabernero, A J, González-Enguita, C, Fernández, J M, García-Escudero, A, Gómez-Veiga, F, Méndez, M J, Segarra, J, Virizuela, J A, Carles, J, Lassa, A, Calderero, V, Constela, M, Delgado, D, Mañas, A, Murias, A, Reynes, G, Rodriguez, B, Rubio, G, Sánchez, E, Unda, M, Solsona, E, Martínez-Javaloyas, J M, Comet-Batlle, J, Quicios, C, Martín-Fernández, M, Mahillo-Fernández, I, Morote, J
Publicado 2013